|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...3233343536373839404142...4647» |
- |||| SAR110894D / Sanofi
Trial completion: Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil (clinicaltrials.gov) - Mar 7, 2013
P2, N=291, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed
- Clinical: Oral Health Intervention Pilot Study for Individuals With Memory Problems (clinicaltrials.gov) - Mar 7, 2013
P=N/A, N=5, Recruiting, Sponsor: Duke University
- ||||| PF-02545920 / Pfizer
New P2 trial: Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease (clinicaltrials.gov) - Mar 5, 2013
P2, N=56, Recruiting, Sponsor: Pfizer
- || Trial completion: A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - Mar 5, 2013
P2/3, N=48, Completed, Sponsor: Avid Radiopharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: AMIMAGE 2: Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=400, Recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Initiation date: Apr 2012 --> Sep 2012
- Enrollment open: AMIMAGE 2: Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study (clinicaltrials.gov) - Feb 26, 2013
P=N/A, N=400, Recruiting, Sponsor: University Hospital, Bordeaux
Initiation date: Apr 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- | Trial completion: Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions (clinicaltrials.gov) - Feb 25, 2013
P2, N=49, Completed, Sponsor: Ipsen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change: CFCC: Cognitive Changes in Adult Cancer Survivors (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=13, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=25 --> 13
- Trial completion: CICI: Chemotherapy-Induced Cognitive Impairment (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=28, Completed, Sponsor: Jay F. Piccirillo, MD
N=25 --> 13 Recruiting --> Completed
- Trial completion: CFCC: Cognitive Changes in Adult Cancer Survivors (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=13, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed Recruiting --> Completed
- Trial completion: Perioperative Risk Factors for Postoperative Delirium in Children (clinicaltrials.gov) - Feb 23, 2013
P=N/A, N=300, Completed, Sponsor: Huazhong University of Science and Technology
Recruiting --> Completed Recruiting --> Completed
- Enrollment change, Surgery: Postoperative Melatonin Administration and Delirium Prevention in Patients Undergoing Vascular and Cardiac Surgery (clinicaltrials.gov) - Feb 20, 2013
P=N/A, N=100, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Completed N=302 --> 100
- |||| AZD-5213 / AstraZeneca
Trial completion: A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment (clinicaltrials.gov) - Feb 20, 2013
P2a, N=81, Completed, Sponsor: AstraZeneca
N=302 --> 100 Active, not recruiting --> Completed
- Trial completion, Surgery: Postoperative Melatonin Administration and Delirium Prevention in Patients Undergoing Vascular and Cardiac Surgery (clinicaltrials.gov) - Feb 20, 2013
P=N/A, N=100, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Austedo (deutetrabenazine) / Teva
New P3 trial: First-HD: First Time Use of SD-809 in Huntington Disease (clinicaltrials.gov) - Feb 19, 2013
P3, N=90, Recruiting, Sponsor: Auspex Pharmaceuticals, Inc.
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, New P1 trial: A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients (clinicaltrials.gov) - Feb 18, 2013
P1, N=47, Completed, Sponsor: AstraZeneca
- sevoflurane / Generic mfg.
Enrollment open: The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane (clinicaltrials.gov) - Feb 16, 2013
P=N/A, N=120, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
Recruiting --> Completed Active, not recruiting --> Recruiting
- Enrollment change: DEVIT-ALZ: The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 14, 2013
P=N/A, N=502, Completed, Sponsor: Gulhane Military Medical Academy
Active, not recruiting --> Recruiting N=1000 --> 502
- Clinical: Cognitive Rehabilitation in Sickle Cell Disease (clinicaltrials.gov) - Feb 14, 2013
P=N/A, N=30, Recruiting, Sponsor: Duke University
- Apidra (insulin glulisine) / Sanofi
Enrollment closed: Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients. (clinicaltrials.gov) - Feb 14, 2013
P2, N=12, Active, not recruiting, Sponsor: HealthPartners Institute for Education and Research
N=1000 --> 502 Recruiting --> Active, not recruiting
- Trial completion: DEVIT-ALZ: The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease (clinicaltrials.gov) - Feb 14, 2013
P=N/A, N=502, Completed, Sponsor: Gulhane Military Medical Academy
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Enrollment change: Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Feb 14, 2013
P2a, N=86, Completed, Sponsor: Pfizer
Recruiting --> Completed N=120 --> 86
- |||| vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Trial completion: Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Feb 14, 2013
P2a, N=86, Completed, Sponsor: Pfizer
N=120 --> 86 Recruiting --> Completed
- | Trial completion: Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease (clinicaltrials.gov) - Feb 13, 2013
P4, N=20, Completed, Sponsor: New York University School of Medicine
Recruiting --> Completed Recruiting --> Completed
- | New P2 trial: Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia (Allena-Mente). (clinicaltrials.gov) - Feb 13, 2013
P2, N=121, Active, not recruiting, Sponsor: Fondazione Golgi Cenci
- ||| bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Biomarker, Enrollment change: SUMMIT AD: Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Feb 12, 2013
P2, N=146, Completed, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting --> Completed N=120 --> 146
- | citalopram / Generic mfg.
Enrollment closed: Citalopram for Agitation in Alzheimer's Disease (clinicaltrials.gov) - Feb 12, 2013
P3, N=200, Active, not recruiting, Sponsor: JHSPH Center for Clinical Trials
N=120 --> 146 Recruiting --> Active, not recruiting
- |||| bapineuzumab (AAB-001) / Pfizer, J&J, Perrigo Company
Biomarker, Trial completion: SUMMIT AD: Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Feb 12, 2013
P2, N=146, Completed, Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | dexmedetomidine / Generic mfg.
HEOR: SKY-DEX: Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients? (clinicaltrials.gov) - Feb 11, 2013
P4, N=100, Recruiting, Sponsor: Maisonneuve-Rosemont Hospital
- Biomarker, Trial termination: BioCogS: A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein). (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=29, Terminated, Sponsor: Nantes University Hospital
Active, not recruiting --> Completed Recruiting --> Terminated; Difficulties of recruitment in a randomization arm
- Biomarker, Enrollment change: BioCogS: A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein). (clinicaltrials.gov) - Feb 10, 2013
P=N/A, N=29, Terminated, Sponsor: Nantes University Hospital
Recruiting --> Terminated; Difficulties of recruitment in a randomization arm N=39 --> 29
- ||| Enrollment change: Clinical Evaluation of Florbetapir F 18 (18F-AV-45) (clinicaltrials.gov) - Feb 7, 2013
P2, N=1800, Recruiting, Sponsor: Avid Radiopharmaceuticals
N=39 --> 29 N=600 --> 1800
- resveratrol (DB02709) / Alzheimer's Disease Cooperative Study
Biomarker, Enrollment closed: Resveratrol for Alzheimer's Disease (clinicaltrials.gov) - Feb 7, 2013
P2, N=120, Active, not recruiting, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
N=600 --> 1800 Recruiting --> Active, not recruiting
- ||| itanapraced (CHF-5074) / CereSpir
Enrollment change: CT04 POLEP: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase (clinicaltrials.gov) - Feb 7, 2013
P2, N=51, Completed, Sponsor: Chiesi Pharmaceuticals Inc.
Recruiting --> Active, not recruiting N=30 --> 51
- |||| itanapraced (CHF-5074) / CereSpir
Trial completion: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP) (clinicaltrials.gov) - Feb 7, 2013
P2, N=74, Completed, Sponsor: Chiesi Pharmaceuticals Inc.
N=30 --> 51 Enrolling by invitation --> Completed
- | elenbecestat (E2609) / Eisai, Biogen
Trial completion: An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption (clinicaltrials.gov) - Feb 5, 2013
P1, N=18, Completed, Sponsor: Eisai Inc.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- | vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer
Trial completion: Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - Feb 5, 2013
P2a, N=32, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: ADNI-GO: Alzheimer's Disease Neuroimaging Initiative Grand Opportunity (clinicaltrials.gov) - Feb 3, 2013
P=N/A, N=342, Completed, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
Active, not recruiting --> Completed N=700 --> 342
- Enrollment open: pré MATAPA: Alzheimer Disease : Rehabilitation's Intervention at Home (clinicaltrials.gov) - Feb 3, 2013
P=N/A, N=30, Recruiting, Sponsor: Nantes University Hospital
N=700 --> 342 Not yet recruiting --> Recruiting
- Trial completion: ADNI-GO: Alzheimer's Disease Neuroimaging Initiative Grand Opportunity (clinicaltrials.gov) - Feb 3, 2013
P=N/A, N=342, Completed, Sponsor: Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Targretin oral (bexarotene oral) / ReXceptor
New P2 trial: BEAT-AD: Bexarotene Amyloid Treatment for Alzheimer's Disease (clinicaltrials.gov) - Jan 31, 2013
P2, N=20, Active, not recruiting, Sponsor: The Cleveland Clinic
- Trial completion: A Study of Florbetapir (18F) in Japanese Healthy Volunteers (clinicaltrials.gov) - Jan 31, 2013
P1, N=7, Completed, Sponsor: Avid Radiopharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Neuroprotection by Cannabinoids in Huntington's Disease (clinicaltrials.gov) - Jan 30, 2013
P2, N=25, Completed, Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| lorazepam / Generic mfg.
New P1 trial: The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms (clinicaltrials.gov) - Jan 29, 2013
P1, N=75, Recruiting, Sponsor: Mayo Clinic
- Enrollment change: Central Auditory Processing Disorders Associated With Blast Exposure (clinicaltrials.gov) - Jan 27, 2013
P=N/A, N=84, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed N=200 --> 84
- IO biomarker: IMABio3: Central and Systemic Inflammation in Alzheimer's Disease (clinicaltrials.gov) - Jan 23, 2013
P=N/A, N=170, Recruiting, Sponsor: Assistance Publique - H
- HEOR: MBCT_AD: Mindfulness Research Program: Designed to Enhance Wellbeing in People Living With Dementia and Their Spouses (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=60, Not yet recruiting, Sponsor: Lakehead University
- Biomarker, Enrollment open: Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department (clinicaltrials.gov) - Jan 22, 2013
P=N/A, N=300, Recruiting, Sponsor: Minneapolis Medical Research Foundation
N=200 --> 84 Not yet recruiting --> Recruiting
- |||| Trial completion: Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease (clinicaltrials.gov) - Jan 22, 2013
P4, N=60, Completed, Sponsor: Florida Atlantic University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Enrollment open: Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) (clinicaltrials.gov) - Jan 20, 2013
P=N/A, N=90, Enrolling by invitation, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation